Inactive Instrument

Press Releases Reata Pharmaceuticals, Inc.

Equities

RETA

US75615P1030

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Chronic Kidney Disease Pipeline, FDA Approvals, Clinical Trials Developments, Companies 2023 \| Boehringer Ingelheim, Eli Lilly and Company, Reata Pharmaceuticals, Novo Nordisk, Prokidney, and others.	Dec. 05	AQ
Biogen Completes Acquisition of Reata Pharmaceuticals	23-09-26	AQ
Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.	23-09-21	BU
REATA PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Reata Pharmaceuticals, Inc. - RETA	23-08-28	BU
REATA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Reata Pharmaceuticals, Inc. - RETA	23-08-02	BU
Reata Pharmaceuticals : VOTING AND SUPPORT AGREEMENT - Form 8-K	23-07-31	PU
Biogen to acquire rare disease drugmaker for $7.3b	23-07-31	AQ
Reata Pharmaceuticals : Announces Biogen to Acquire Reata Pharmaceuticals	23-07-28	PU
Shareholder Alert: Ademi LLP investigates whether Reata Pharmaceuticals, Inc. has obtained a Fair Price in its Private Placement and its transaction with Biogen	23-07-28	PR
Biogen to bulk up rare disease treatments with $7 billion Reata acquisition	23-07-28	AQ
RETA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Reata Pharmaceuticals, Inc. Is Fair to Shareholders	23-07-28	BU
Reata Pharmaceuticals Announces Approval of Prior Approval Supplement for SKYCLARYS® (Omaveloxolone) and Commercial Availability of SKYCLARYS for Patients with Friedreich’s Ataxia	23-06-27	BU
Reata Pharmaceuticals Announces FDA Filing Acceptance of SKYCLARYS NDA Prior Approval Supplement	23-06-16	AQ
Reata Pharmaceuticals Announces FDA Filing Acceptance of SKYCLARYS® (Omaveloxlone) NDA Prior Approval Supplement	23-06-15	BU
Reata Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President, Chief Research & Development Officer	23-06-13	BU
RETA ALERT: The Law Offices of Vincent Wong Investigate Reata Pharmaceuticals, Inc. for Potential Violations of Securities Laws	23-06-12	PR
RETA FRAUD ALERT: Jakubowitz Law is Investigating Reata Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws	23-06-09	PR
RETA Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Reata Pharmaceuticals, Inc.	23-06-08	PR
INVESTIGATION ALERT: The Gross Law Firm Notifies Shareholders of Reata Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit - (NASDAQ: RETA)	23-06-07	PR
Reata Pharmaceuticals Announces Participation in the Goldman Sachs 44th Annual Global Healthcare Conference	23-06-06	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Reata Pharmaceuticals, Inc.

Equities

RETA

US75615P1030

Press Releases

Filters